Evotec AG (EVTG.F) And Eternygen Enter Collaboration To Identify And Develop Novel Metabolic Disease Therapy
5/6/2014 10:00:02 AM
BERLIN and HAMBURG, Germany, May 6, 2014 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development. Eternygen is working on the sodium coupled citrate transporter NaCT, a novel target which is a key regulator of energy metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.
Help employers find you! Check out all the jobs and post your resume.
comments powered by